Gynecologic Oncology Practice Questions

Q: According to the FIGO staging for endometrial carcinoma, which stage includes involvement of paraaortic lymph nodes?

Stage IIIc. **Explanation:** The staging of endometrial carcinoma follows the **FIGO (2023/2009) surgical staging system**. The correct answer is **Stage IIIc**, which specifically denotes metastasis to the pelvic and/or para-aortic lymph nodes. * **Why Stage IIIc is correct:** Stage III represents local and/or regional spread of the tumor. It is subdivided into: * **IIIc1:** Metastasis to pelvic lymph nodes only. * **IIIc2:** Metastasis to **paraaortic lymph nodes**, with or without pelvic node involvement. * The presence of nodal involvement significantly changes the prognosis and dictates the need for adjuvant radiation or chemotherapy. * **Analysis of Incorrect Options:** * **Stage IIIb:** Refers to vaginal and/or parametrial involvement. * **Stage IVa:** Refers to tumor invasion of the bladder and/or bowel mucosa. * **Stage IVb:** Refers to distant metastasis, including intra-abdominal disease (omental) or inguinal lymph nodes (which are considered distant, unlike pelvic/paraaortic nodes). **High-Yield Clinical Pearls for NEET-PG:** * **Surgical Staging:** Endometrial cancer is primarily staged **surgically** (unlike cervical cancer, which was traditionally clinical but is now a hybrid). * **Most Common Histology:** Endometrioid adenocarcinoma is the most common type. * **Sentinel Lymph Node (SLN) Mapping:** This is increasingly used in early-stage disease to reduce the morbidity of complete lymphadenectomy while accurately identifying Stage IIIc disease. * **Red Flag:** Any postmenopausal bleeding must be investigated via endometrial biopsy or fractional curettage to rule out malignancy.

Q: What is the most common cause of cervical neoplasia?

Human Papillomavirus (HPV) type 16. **Explanation:** The primary etiological factor in the development of cervical neoplasia (both squamous cell carcinoma and adenocarcinoma) is persistent infection with **High-Risk Human Papillomavirus (hrHPV)**. **Why Option C is correct:** Among the high-risk types, **HPV 16** is the most potent and prevalent globally. It is responsible for approximately **50-60%** of all cervical cancers. HPV 16 produces E6 and E7 oncoproteins, which degrade the p53 and pRb tumor suppressor proteins, respectively, leading to uncontrolled cell cycle progression and malignant transformation. **Why other options are incorrect:** * **Options A & B (HPV 6 and 11):** These are classified as **Low-Risk HPV** types. They are primarily associated with benign lesions such as Condyloma Acuminata (genital warts) and Recurrent Respiratory Papillomatosis. They rarely cause malignancy. * **Option D (HHV):** Human Herpesviruses (like HSV-2) were once thought to be involved, but they are now considered "co-factors" or bystanders rather than the primary causative agent of cervical neoplasia. **High-Yield Clinical Pearls for NEET-PG:** * **HPV 16:** Most common cause of Squamous Cell Carcinoma (SCC). * **HPV 18:** Second most common type (10-15%) and has a strong association with **Adenocarcinoma**. * **Screening:** The transformation zone is the most common site for cervical neoplasia. * **Vaccination:** The 9-valent vaccine (Gardasil 9) covers types 6, 11, 16, 18, 31, 33, 45, 52, and 58. * **Most common symptom:** Post-coital bleeding is the classic clinical presentation of cervical cancer.

Q: A 23-year-old patient is diagnosed with stage IA malignant ovarian germ cell tumor. What is the standard treatment?

Unilateral oophorectomy followed by chemotherapy. **Explanation:** The standard management for Malignant Ovarian Germ Cell Tumors (MOGCTs) differs significantly from epithelial ovarian cancer because MOGCTs are typically unilateral, occur in young women, and are highly chemosensitive. **Why Option C is Correct:** For a 23-year-old with Stage IA MOGCT, the goal is to preserve fertility while ensuring oncological safety. The standard treatment is **Fertility-Sparing Surgery (Unilateral Salpingo-oophorectomy)** followed by **adjuvant chemotherapy** (typically the BEP regimen: Bleomycin, Etoposide, and Cisplatin). Even in Stage I, most MOGCTs (except for Grade 1 Immature Teratoma and Stage IA Dysgerminoma) require chemotherapy due to their aggressive nature and high risk of occult metastasis. **Why Other Options are Incorrect:** * **Option A:** Unilateral oophorectomy alone is insufficient for most MOGCTs (except Stage IA Dysgerminoma or Grade 1 Immature Teratoma) as the recurrence risk is high without systemic therapy. * **Option B:** Bilateral oophorectomy and hysterectomy is overly aggressive for a young patient and is generally reserved for postmenopausal women or advanced epithelial cancers. * **Option C:** Ovarian biopsy is contraindicated in suspected ovarian malignancy as it can cause "spillage" of tumor cells, upstaging the disease from Stage I to Stage IC. **NEET-PG High-Yield Pearls:** * **Most common MOGCT:** Dysgerminoma (associated with LDH marker). * **Tumor Markers:** Yolk Sac Tumor (AFP), Choriocarcinoma (hCG), Dysgerminoma (LDH/PLAP). * **Chemosensitivity:** MOGCTs are the most chemosensitive solid tumors in gynaecology. * **Exception to Chemo:** Stage IA Dysgerminoma and Stage I Grade 1 Immature Teratoma can be managed with surgery and observation alone.

Q: Carcinoma of the endometrium with superficial inguinal lymph node involvement is classified as which stage?

Stage IV. **Explanation:** The staging of Endometrial Carcinoma follows the **FIGO (2023)** classification. The correct answer is **Stage IV** because the involvement of **inguinal lymph nodes** represents distant metastasis. 1. **Why Stage IV is correct:** In endometrial cancer, lymphatic spread typically follows the pelvic and para-aortic chains. The **superficial inguinal nodes** are considered **distant lymph nodes** (similar to supraclavicular nodes). According to FIGO staging, involvement of distant lymph nodes, including inguinal nodes, or metastasis to distant organs (lung, liver, bone) and abdominal serosa, classifies the disease as **Stage IVB**. 2. **Why Stage III is incorrect:** Stage III involves local or regional spread within the pelvis. Stage IIIC specifically refers to metastasis to **pelvic (IIIC1)** or **para-aortic (IIIC2)** lymph nodes. Inguinal nodes are outside this regional boundary. 3. **Why Stage II is incorrect:** Stage II is limited to the **cervical stromal invasion** but does not extend beyond the uterus. 4. **Why Stage I is incorrect:** Stage I is confined to the **corpus uteri** (IA: <50% myometrial invasion; IB: ≥50% myometrial invasion). **High-Yield Clinical Pearls for NEET-PG:** * **Most common site of distant metastasis:** Lungs. * **Lymphatic drainage:** The fundus drains to para-aortic nodes; the lower segment drains to pelvic nodes; however, a small portion of the fundus near the round ligament can drain directly to **inguinal nodes** (rare but diagnostic of Stage IVB). * **Most common histological type:** Endometrioid adenocarcinoma. * **Prognostic factor:** The depth of myometrial invasion and nodal involvement are the most significant predictors of survival.

Q: A 20-year-old female is diagnosed with a granulosa cell tumor of the ovary. Which of the following biomarkers would be most useful for patient follow-up?

Inhibin. **Explanation:** Granulosa cell tumors (GCTs) are the most common type of malignant sex cord-stromal tumors. They are unique because they arise from cells that normally produce hormones in the ovarian follicle. **1. Why Inhibin is the Correct Answer:** Granulosa cells naturally secrete **Inhibin** (specifically Inhibin B) to provide negative feedback on FSH. In patients with GCTs, Inhibin levels are significantly elevated. It serves as a highly sensitive and specific tumor marker for both the **initial diagnosis** and, more importantly, for **monitoring recurrence** during follow-up. A rise in Inhibin levels often precedes clinical or radiological evidence of recurrence by several months. **2. Analysis of Incorrect Options:** * **CA50:** This is a non-specific carbohydrate antigen marker primarily associated with gastrointestinal and pancreatic malignancies, not ovarian sex cord tumors. * **CA 19-9:** This is the primary marker for **pancreatic adenocarcinoma** and is also elevated in mucinous tumors of the ovary. * **Neuron-specific enolase (NSE):** This is a marker for neuroendocrine tumors (like small cell lung cancer) and certain germ cell tumors like **dysgerminomas** or immature teratomas. **3. Clinical Pearls for NEET-PG:** * **Estrogen Production:** GCTs are "functioning tumors" that secrete estrogen. In young patients (like the one in this case), this can lead to **precocious puberty**; in older patients, it causes **postmenopausal bleeding** and increases the risk of endometrial hyperplasia/carcinoma. * **Histology:** Look for **Call-Exner bodies** (small follicles filled with eosinophilic material) and "coffee-bean" nuclei. * **Other Markers:** While Inhibin is the gold standard, **Anti-Müllerian Hormone (AMH)** is also a highly specific marker for GCT follow-up.

Q: Which virus is responsible for causing cervical cancer in the ectocervix?

HPV16. **Explanation:** Human Papillomavirus (HPV) is the primary etiological agent for cervical cancer. Among the high-risk (oncogenic) types, **HPV 16** is the most prevalent, accounting for approximately 50-60% of all cervical squamous cell carcinomas (which typically arise from the ectocervix). **Why the correct answer is right:** HPV 16 and 18 are classified as high-risk because their E6 and E7 oncoproteins inhibit tumor suppressor proteins **p53** and **pRb**, respectively. This leads to uncontrolled cell proliferation and genomic instability. While HPV 16 is most associated with squamous cell carcinoma (ectocervix), HPV 18 is more frequently linked to adenocarcinoma (endocervix). **Analysis of incorrect options:** * **HPV 17 & 19:** These are not recognized as major high-risk oncogenic types in the context of cervical cancer screening or pathogenesis. * **HPV 11:** This is a **low-risk** HPV type. Along with HPV 6, it is responsible for 90% of genital warts (Condyloma acuminatum) and recurrent respiratory papillomatosis, but it rarely causes malignancy. **High-Yield Clinical Pearls for NEET-PG:** * **Most common HPV type in Cervical Cancer:** HPV 16 (Global and India). * **Most common HPV type in Adenocarcinoma:** HPV 18. * **Vaccination:** The Quadrivalent vaccine (Gardasil) covers types 6, 11, 16, and 18. The Nonavalent vaccine adds types 31, 33, 45, 52, and 58. * **Screening:** The Transformation Zone (TZ) is the most common site for neoplastic changes. * **Oncoprotein Mnemonic:** **E6** affects p**5**3 (6-5) and **E7** affects **R**b (7-R).

Q: What is the most common type of vaginal carcinoma?

Squamous cell carcinoma. **Explanation:** **Primary vaginal cancer** is a rare malignancy, as most vaginal cancers are metastatic (usually from the cervix or endometrium). Among primary vaginal cancers, **Squamous Cell Carcinoma (SCC)** is the most common histological type, accounting for approximately **80–90%** of cases. It typically arises from the squamous epithelium lining the vagina and is most frequently seen in postmenopausal women. Like cervical cancer, it is strongly associated with high-risk **Human Papillomavirus (HPV)** infection, particularly types 16 and 18. **Analysis of Incorrect Options:** * **B. Adenocarcinoma:** This accounts for about 5–10% of cases. A specific subtype, **Clear Cell Adenocarcinoma**, is classically associated with *in utero* exposure to **Diethylstilbestrol (DES)**. * **C. Botryoid Sarcoma (Sarcoma Botryoides):** This is a subtype of embryonal rhabdomyosarcoma. While it is the most common vaginal tumor in **infants and children** (typically <5 years old), it is rare in the general population. It characteristically presents as a "cluster of grapes" protruding from the vagina. * **D. Columnar Hyperplasia:** This is a benign histological change (often related to vaginal adenosis) and is not a type of carcinoma. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** The **upper 1/3rd of the posterior vaginal wall** is the most frequent location for primary vaginal SCC. * **FIGO Staging:** Vaginal cancer is staged **clinically**. * **Lymphatic Drainage:** This is a favorite exam topic. The **upper 2/3rd** drains to the **pelvic nodes** (iliac nodes), while the **lower 1/3rd** drains to the **superficial inguinal nodes**. * **Treatment:** Radiotherapy is the mainstay of treatment for most stages of vaginal cancer.

Q: Which tumor marker is most helpful in the follow-up of a case of epithelial carcinoma of the ovary?

CA-125. **Explanation:** **CA-125 (Cancer Antigen 125)** is the gold standard tumor marker for **Epithelial Ovarian Cancer (EOC)**, which accounts for approximately 90% of all ovarian malignancies. Its primary clinical utility lies in **monitoring treatment response** and **detecting recurrence** during follow-up. A rising trend in CA-125 levels often precedes clinical or radiological evidence of disease recurrence by several months. While it is also used in the diagnostic workup (especially in postmenopausal women), its high sensitivity for serous cystadenocarcinoma makes it indispensable for longitudinal follow-up. **Analysis of Incorrect Options:** * **B. Serum Alpha-Fetoprotein (AFP):** This is the specific marker for **Yolk Sac Tumors** (Endodermal Sinus Tumors). It is also elevated in some immature teratomas and hepatocellular carcinoma. * **C. Serum human chorionic gonadotropin (hCG):** This is the marker for **Nongestational Choriocarcinoma** and is also elevated in **Dysgerminomas** (if syncytiotrophoblastic giant cells are present). * **D. Human Placental Lactogen (hPL):** This is primarily a marker for **Placental Site Trophoblastic Tumor (PSTT)**; it has no role in the management of epithelial ovarian cancer. **High-Yield Clinical Pearls for NEET-PG:** * **Normal Value:** < 35 U/mL. * **Specificity Issue:** CA-125 can be elevated in benign conditions like endometriosis, PID, fibroids, and pregnancy, particularly in premenopausal women. * **Germ Cell Tumors:** Always remember the "Marker-Tumor" pairs: LDH for Dysgerminoma, AFP for Yolk Sac Tumor, and Inhibin B for Granulosa Cell Tumor (Sex-cord stromal). * **Struma Ovarii:** Associated with elevated Thyroxine (T4).

Q: Cone biopsy is indicated in all the following conditions except?

Cervical metaplasia. **Explanation:** **Cervical metaplasia** (specifically squamous metaplasia) is a **normal physiological process** occurring at the transformation zone where columnar epithelium is replaced by squamous epithelium. It is not a premalignant condition and requires no surgical intervention. Therefore, a cone biopsy—an invasive procedure—is never indicated for metaplasia. **Why other options are indications for Cone Biopsy:** * **Indefinite diagnosis on colposcopy:** If the colposcopic examination is "unsatisfactory" (e.g., the squamocolumnar junction is not fully visualized) or if there is a discrepancy between the Pap smear (high-grade) and the biopsy (low-grade), a cone biopsy is mandatory to rule out occult malignancy. * **CIN-III:** High-grade squamous intraepithelial lesions (HSIL/CIN-III) require definitive treatment to prevent progression to invasive cancer. Conization serves as both a diagnostic and therapeutic (excisional) procedure. * **Microinvasive carcinoma (Stage IA1):** Cone biopsy is the gold standard for diagnosing the depth of invasion. If the margins are clear and the depth is <3mm with no lymphovascular space invasion (LVSI), conization can also be the definitive treatment for women wishing to preserve fertility. **NEET-PG High-Yield Pearls:** * **Diagnostic vs. Therapeutic:** Conization is unique because it provides a large tissue sample for histopathology (diagnostic) while simultaneously removing the lesion (therapeutic). * **The "Rule of Discrepancy":** If Cytology (Pap) > Biopsy or Colposcopy, proceed to Cone Biopsy. * **Complications:** The most common immediate complication is **hemorrhage** (descending branch of the uterine artery); the most common long-term complication is **cervical incompetence** (leading to mid-trimester abortions) or cervical stenosis.

Q: Which lymph nodes are typically not involved in carcinoma of the endometrium?

Inferior mesenteric. **Explanation:** The lymphatic drainage of the endometrium follows the arterial supply and embryonic development of the uterus. The primary drainage pathways are through the **external iliac, internal iliac, and obturator nodes**, eventually reaching the **para-aortic nodes**. **Why Inferior Mesenteric is the Correct Answer:** The **inferior mesenteric lymph nodes** drain the descending colon, sigmoid colon, and upper rectum. They are not part of the standard lymphatic drainage pathway for the female genital tract. While endometrial cancer can spread to the para-aortic nodes (near the origin of the renal vessels), it does not typically involve the inferior mesenteric chain unless there is extensive, non-anatomical intraperitoneal carcinomatosis. **Analysis of Other Options:** * **Para-aortic (A):** High-yield fact! Lymphatics from the uterine fundus follow the ovarian vessels directly to the para-aortic nodes. This is a common site for "skip metastases." * **Presacral (B):** Lymphatics from the lower uterine segment and cervix can drain via the uterosacral ligaments to the presacral nodes. * **Inguinal (C):** Though rare, involvement occurs when the tumor spreads along the **round ligament** to the superficial inguinal nodes. This is a classic "high-yield" anatomical variant for exams. **NEET-PG High-Yield Pearls:** 1. **Most common site of spread:** Direct extension to the myometrium. 2. **Most common LN involvement:** Pelvic lymph nodes (Obturator nodes are often the first involved). 3. **Sentinel Lymph Node (SLN) Mapping:** Now the preferred standard in early-stage endometrial cancer to reduce the morbidity of full lymphadenectomy. 4. **Staging:** Endometrial cancer is **surgically staged** (FIGO). Involvement of pelvic nodes is Stage IIIC1, and para-aortic nodes is Stage IIIC2.

Question 1

According to the FIGO staging for endometrial carcinoma, which stage includes involvement of paraaortic lymph nodes?

Accepted Answer

Stage IIIc

Answer

Stage IIIb

Answer

Stage IVa

Answer

Stage IVb

Question 2

What is the most common cause of cervical neoplasia?

Accepted Answer

Human Papillomavirus (HPV) type 16

Answer

Human Papillomavirus (HPV) type 6

Answer

Human Papillomavirus (HPV) type 11

Answer

Human Herpesvirus (HHV)

Question 3

A 23-year-old patient is diagnosed with stage IA malignant ovarian germ cell tumor. What is the standard treatment?

Accepted Answer

Unilateral oophorectomy followed by chemotherapy

Answer

Unilateral oophorectomy

Answer

Bilateral oophorectomy and hysterectomy

Answer

Ovarian biopsy followed by chemotherapy

Question 4

Carcinoma of the endometrium with superficial inguinal lymph node involvement is classified as which stage?

Accepted Answer

Stage IV

Answer

Stage III

Answer

Stage II

Answer

Stage I

Question 5

A 20-year-old female is diagnosed with a granulosa cell tumor of the ovary. Which of the following biomarkers would be most useful for patient follow-up?

Accepted Answer

Inhibin

Answer

CA50

Answer

CA 19-9

Answer

Neuron-specific enolase

Question 6

Which virus is responsible for causing cervical cancer in the ectocervix?

Accepted Answer

HPV16

Answer

HPV17

Answer

HPV11

Answer

HPV19

Question 7

What is the most common type of vaginal carcinoma?

Accepted Answer

Squamous cell carcinoma

Answer

Adenocarcinoma

Answer

Botryoid sarcoma

Answer

Columnar hyperplasia

Question 8

Which tumor marker is most helpful in the follow-up of a case of epithelial carcinoma of the ovary?

Accepted Answer

CA-125

Answer

Serum Alpha Fetoprotein

Answer

Serum human chorionic gonadotropin

Answer

Human Placental Lactogen

Question 9

Cone biopsy is indicated in all the following conditions except?

Accepted Answer

Cervical metaplasia

Answer

Indefinite diagnosis on colposcopy

Answer

CIN-III

Answer

Microinvasive carcinoma

Question 10

Which lymph nodes are typically not involved in carcinoma of the endometrium?

Accepted Answer

Inferior mesenteric

Answer

Para-aortic

Answer

Presacral

Answer

Inguinal

Gynecologic Oncology — MCQs

Gynecologic Oncology — MCQs

On this page

Practice by Chapter

Want unlimited practice?